CPIC 2026 Unveils Updated Agenda Framework Covering All Hot Topics in Global Pharma Innovation
IASO Biotechnology
Cancer Treatment New Drug Developer
Click to view the conference planning team lineup?
Chinese New Drugs Are Reshaping the Global Innovation Landscape.
Halfway through 2026, the industrial surge is in full swing—BD deals are reshaping the rules, cutting-edge technologies are breaking through boundaries, and capital logic is subtly shifting. This is not a localized warming, but a generational transition.
The times call for a commensurate agenda.
CPIC 2026: Adapting to the Times, Comprehensively Upgraded. Deeper Topics, Stronger Lineup, Broader Vision. Today, the Latest Agenda Framework is Officially Unveiled.
60+ Specialized Sessions, 300+ Topics: From CNS to CGT, from AI-Driven Drug Discovery to Radiopharmaceuticals, and from Cross-Border Business Development to Capital M&A—Every Sector Is Riding the Crest of the Wave in 2026.
The prestige of CPIC 2026 speaks for itself. July 22–24, National Exhibition and Convention Center (Shanghai). For the first time, Chinese new drugs are setting their own coordinates and issuing an agenda to the world.
Last 3 Weeks for Early Bird Tickets: 25% Off Ending Soon. Over 100 Companies Have Secured Booths.
Sitting with Academicians, Walking with Industry Leaders, Resonating with the Times.
Guiding Organization |Shanghai Biomedical Science and Technology Industry Promotion Center, Shanghai Innovative Drug R&D Center, Shanghai Institute for Global Health Innovation
Organizer |Tongxieyi
Co-Hosted by|Shanghai Domestic Production and Education Integration Innovation Center (Preparatory)
Strategic Cooperation |School of Biotechnology, Fudan University; Guangzhou Pharmaceutical Holdings Limited (GPHL); WuXi AppTec; WuXi Biologics; Tofflon; Ernst & Young (EY); Fangda Partners; Legend Capital; China Chamber of Commerce for Import and Export of Medicines and Health Products
Click on the session name to view the detailed schedule
Biomedicine as China's Emerging Pillar Industry
Global Frontiers of Biomedical Innovation
The Path of Chinese Pharmaceutical Companies Toward Becoming MNCs
FIC and World-Class Drug Development
Innovative Drugs in China: Efficiency and Continuous Evolution
CPIC Results Release
CPIC Honors Awards
ChengZengjiang：Co-founder of Tongxieyi, Executive Chairman of CPIC 2026
Wu Xiaobin:Founder of the China Innovative Drug Commercialization 50 Forum, President and Chief Operating Officer of BeiGene
Lu Mingfang:Founding Chairman of the China Healthcare Investment 50 Forum, Partner at FountainVest Partners, and Former Chairman of Shanghai Pharmaceutical Group
CNS Innovative Drug R&D Special Session
Co-organized by:Hanshu Biomedical, Quark Medicine
Wang Yutian:Professor, Shangsi Center for Neuroscience at Fudan University; Fellow of the Royal Society of Canada; Founder and Chairman of Pudirui Pharmaceuticals
Guo Fei:Hanshu Scientific Advisor
Yuan Dawei:Founder, Chairman and General Manager of Beijing Quark Pharmaceutical Group
Shen Huaqiong:Founder and CEO of NuOshen Pharma
ATMP and CGT Global Expansion Special Session
Co-organizers:IASO Bio
Zhang Jinhua:Chairman and CEO of IASO Bio
Innovative Gene Therapy Session
Co-organizer of the Special Session:Xingcheng Bio
Liu Xiao:Vice President of Xingcheng Bio, Chief Brand Officer of Tongxieyi
Cai Yuan:Head of AAV, Shanda Network Metabolic Health Laboratory
Gao Lu:CEO of Youyin Pharma
Special Session on New Technologies in Stem Cells and Regenerative Medicine
Co-organizers: Vcanbio; Session Co-organizer: ExCell Bio
Zhang Yu:President of Vcanbio, Chairman of the Tongxieyi CGT Club
Special Session on Patient-Centered Innovative Practices in the R&D of Novel Stem Cell Therapies
Co-organizer of the Special Session:Saijun Bio
Shen Yutian：CEO of Guangzhou Saijun Biotechnology
Advanced Stem Cell Culture Process Special Session
Co-organized by:Suzhou Youyi Biotechnology, Zhejiang Jinyi Shengshi
Xiao Shang:Founder and Chairman of Suzhou Youyi Bio
Wu Wei:General Manager, Suzhou Youyi Biotech
In Vivo CAR-T and Cell Therapy Special Session
Co-organizer of the Special Session:Hegen Biotech, Vigene Biosciences, Abclonal
Global Special Session on Oligonucleotide Drug Innovation
Co-organizer of the Special Session:Tofflon, InnoCare, ChemPartner, GemPharmatech
Liang Zicai:Chairman and CEO of Ribo Life Science(Chief Planner)
Chang Yan:President of InnoCare
Li Hao:Pharmaron CMO
Special Session on the Future of Innovation in Conjugated Drugs
Co-organizer of the Special Session:Sherpa Bio
Zhou Kaisong:COO of Innovent Biologics Group; CEO and Chairman of the Board of Sherpa Bio
New Molecular Entity Drug R&D Special Session
Co-organizers:WuXi AppTec
Special Session on Innovative Small-Molecule Chemical Drugs
Frontiers in Peptide Drug Development Special Session
Co-organized by:Revvity
Breaking Through: Next-Generation Innovative Therapies Special Session
Co-organizers:Borui Medicine, Langyu Capital
Liu Jin:CEO of Langyu Capital
Yuan Jiandong:Chairman of Borui Medicine
Organoids and Biochips Session
Co-organizer of the Special Session:Qijia Technology
The Booming Radiopharmaceuticals Session
Co-organizers:Baiyunshan Xihe Health
Xu Tao:Founder and CEO of Zhihe Biologics, Secretary-General of the Tongxieyi Radiopharmaceutical Club
Special Session on Anti-Tumor Drug Development
Nanobody Drug Development Special Session
Co-organizer of the Special Session:Baiying Bio
Shi Haikun:Founder and Chairman of Kunyu Bio
Special Session on Non-Clinical Evaluation of Hot Drugs
Co-organizer of the Special Session:JOINN Laboratories
Chen Xiaochun:Deputy General Manager and Co-CSO of Joinn Laboratories
Smart Research for the Future Special Session - AI for Life Science and Drug Discovery
Co-organizer of the Special Session:MegaRobo
Zhang Yan:Co-founder and Senior Vice President of Megga Technology
Xian Xuan:CIO of GenSci Pharmaceutical, Dean of the AI Drug Research Institute
AI4S Reshaping Innovative Drug R&D Special Session
Co-organizer of the Special Session:DP Technology
Sun Weijie:Founder and CEO of DeepModeling
Co-organizers:Fengxu Technology, Shanghai Jiyu Medicine, Shanghai Institute for Clinical Innovation and Translation
Liang Hongming:Co-founder and Chief Scientific Officer of Fengxu Technology
Special Session: AI Reshaping the Entire Clinical R&D Value Chain
Co-organizers:Gena Pharma
Zhao Shanshan:CEO of Jena Pharma
AI-Powered “Four-in-One” Translational Platform: Special Session on Early-Stage R&D for Domestic and International Pharmaceutical Companies
Wen Danyi:Founder, Chairman and CEO of Lead Biology
AI-Driven Innovation Practices in Pharmaceutical Companies: From Benchmark Cases to New Collaboration Paradigms Special Session
Co-organizer of the Special Session:DXY Insight
Special Session on AI Healthcare Innovation Breakthroughs and Future Industrial Layout
Co-organizer of the Special Session:Yuan Yi Capital
Yang Ruirong:Partner at Beijing Yuanyi Capital
Special Session on Changes in U.S. Regulatory Policies and Risk Control
He Ruyi:Dean, Shanghai Institute for Global Health Innovation
Du Tao:Chairman of Aeglin Pharma
Special Session on Decree No. 818 and the Translational Application of New Biomedical Technologies
Co-organizers:Tofflon Life Science
Li Jie:Senior Vice President of Regulatory Affairs at Aeira Health; Director of the Beijing Economic-Technological Development Area Full-Chain Pharmaceutical Information Research Institute
Liu Xiao:Vice President of Xingcheng Bio, Chief Brand Officer of Tongxieyi
Special Session on IIT Regulatory Models and Innovation Efficiency in China
Co-organizer of the Special Session:Wuxi Shengji Pharmaceutical
Li Jie:Senior Vice President of Regulatory Affairs at Aeira Health; Director of the Beijing Economic-Technological Development Area Full-Chain Pharmaceutical Information Research Institute
Zhang Dan:Chairman of Puxin Bio / Chief Scientist at Xiehe Innovation Port
Bioprocessing and Intelligent Manufacturing Special Session
Co-organizers:Hanbang Technology
Ma Jun:Former Vice President of Junshi Biosciences
Li Shengying:Executive President of Hanbang Technology
Co-organized by:Helios
Jia Qijun:Founder and Chairman of IASO Bio
Brain-Computer Interface Special Session
Co-organizer of the Special Session:Qinzhi Capital, BrainCo Technologies
Hou Jinbiao:Fund Partner, QinZhi Capital
Special Session on Internationally Advanced Drug Delivery Systems and Combination Products
Co-organizers:Yi Anshi Medical Technology
Supporting Organizations:Wanhai Medical, Aptar Pharma
Zhang Lijie:Founder of Yi Anshi Medical Technology
Huang Hua:Director and CEO of Yi Anshi Medical Technology
Biomanufacturing Project Pitch Session
Industrial Securities Special Session
Co-organized by:Industrial Securities
Sun Yuanyuan:Executive Deputy Dean of the Economic and Financial Research Institute at Industrial Securities, Chief Pharmaceutical Analyst
Special Session on Chinese Innovative Drugs and the Capital Market
Co-organized by:Soochow Securities
Zhu Guoguang:Co-Director of Soochow Securities Research Institute, Chief Healthcare Analyst
Xiao Hongde:Chief Analyst of Innovative Drugs at Soochow Securities
Special Session on IPO Regulation and Listing Pathways
NewCo: Evolution and Transcendence Special Session
Zhu Jielun:Partner at Button Capital
Wu Jie:Head of MPM Asia-Pacific / K2 CBO
Biopharmaceutical M&A Special Session
Co-Hosted by:Morning哨 Group
Wang Yunfan:Founder of Morning哨 Group
Deng Jianliang:Partner at Tianhui Capital / Founder of Jiazhe Medical & Health
BLPN Global Biopharmaceutical Investors Session
Wu Baofeng:Founder of SaniMed Science Group
Co-organized by:Legend Capital, Rxilient
Hong Tan:Managing Director, Legend Capital
He Lian:CEO of Rxilient Kanglianda
BRICS Special Session: Deepening Engagement in Global Diverse Markets, Delivering the Full-Chain Value of China’s Innovative Drugs
Co-organizers:C50, CanSino Biologics, Tongxieyi
Wang Jing:Executive Director and Chief Commercial Officer of CanSino Biologics
China-Europe Healthcare Industry Special Session
Co-organized by: French Health Industry Alliance, Tongxieyi; Co-organizers: Kinove Bio, EBT
Andreas Penk：Co-founder/CEO of EBT, Former President of Pfizer China
Zhang Fenping:General Manager of Genuvive Bio
China-Japan Cooperation Session: Leveraging the Japanese Market to Drive Global Expansion Strategy
Keiji Kawamoto:Partner Representative, Kawamoto BioBusiness Partners / Senior Advisor, Shanghai Dabang Law Firm (Shanghai)
Dong Ruiping:Founder of Ruiwang Pharmaceutical
Niu Zhengqian:President of Tokyo Cyblan Health Technology Co., Ltd.
Co-organized by:Fangda Law Firm
Li Xiang:Partner at Fangda Law Firm
Zhao Hao:Partner at JunHe LLP
From IP to BD: Special Session on Deal-Making Power in China’s Innovative Drug Transactions
Co-organized by:Merits & Tree Law Firm
Tang Huadong:Partner at Merits & Tree Law Firm
Guo Xiaoxing:Partner at Merits & Tree Law Firm
Huang Xiaolin:Partner at Merits & Tree Law Firm
China-US Collaboration Session: Leveraging Chinese Innovation to Accelerate Global Drug Development
Co-organizer of the Special Session:Uni-Pioneers BioMed
Global BD Collaboration Session for Innovative Drugs 1-2-3
Co-organizer of the Special Session:Bank of Communications Shanghai Branch
Dai Han:Chief Innovation Officer of WuXi Biology and Head of WuXi Biology Innovation Center
Zhang Zhimin:Mentor, QB3/Bakar Biotech Incubator, University of California, Berkeley
Wang Min:PBNY Partner
Ji Xiaohui:CEO of Kewang Pharma
North America-China Innovative Drug Industry Cooperation Session
Bo Zhiquan:International Academy of Applied Technology Research (IATRI)
Zhao Yingchun:Operating Partner at BioInno, Vice President of SAPA-DC, and Director of the Pharmacy Department at IATRI
Special Session on the Global Commercialization of Chinese Biosimilars
Co-organizer of the Special Session:Sinovac Biotech, Auscan Biologics
Shao Ke:Deputy General Manager of Sinovac Biotech
Luo Jiali:CEO of Auscon Biologics Group
Protheragen Special Session: Global Cross-Border Biopharmaceutical Transactions
Co-organized by:Protheragen
Zhang Jiguo:General Manager, Fosun Vaccine
Hong Kong Globalization Opportunities Special Session
Co-organized by:Hong Kong Chinese General Chamber of Commerce, Hong Kong Biomedical Innovation Association
Shen Chenyi:Director of the Secretariat, Hong Kong Chinese General Chamber of Commerce and Industry
Liao Lifang:Director-General of the Hong Kong Biomedical Innovation Association
Global Development Strategies for Novel Oncology Drugs (China, US, and Australia)
Co-organizer of the Special Session:Novotech
Special Session: The Path to Innovative Transformation for Traditional Pharmaceutical Companies
Co-organized by:GPHL
Special Session on the Development of Biomedical Industrial Parks
Sun Xiaomeng:General Manager, Shanghai Minhang Biopharmaceutical Industry Development Co., Ltd.
WRSA Special Session: Innovation and Translation in Chinese Hospitals and Global Competitiveness
Dong Zengjun:Rotating President, Western Returned Scholars Association US Chapter
Li Bin:Vice President of the Shanghai Western Returned Scholars Association, President of the Biomedical Branch, and Deputy Director of the Shanghai Institute of Immunology at Shanghai Jiao Tong University School of Medicine
Co-organizer of the Special Session:USTC Alumni
Hu Yonghan:Xinnuowei CTO
Special Session: Building a New Engine for Cross-Border Biotech Innovation Ecosystems and Industrial Transformation
Sally Sha：Vice President, ELPIS Biopharmaceuticals; Head of China Region
China Biotech: Integrated R&D, Manufacturing, and Sales vs. Specialized Division of Labor Session
Tao Qiucheng:Vice President, Yatai Capital Investment
Special Session: Women Leading the Future of Medical Innovation
Co-organizers:GB·Partner
Jiawei Tang：COO，GB-Partner
Roadshow Session
Co-organizer of the Special Session:Boling Capital
Chen Feng:Founder and CEO of Boling Capital
Click to view the list of the first 100+ exhibitors
The conference features a dedicated 10,000 m² professional exhibition hall for corporate/institutional brand showcasing and business negotiations.
Add this WeChat account to make a reservation
Exclusive Additional Benefits Available at the Conference
Tong Xieyi:010-83634390/83634290
Email:txy@cpic-shanghai.com
Official Website:www.cpic-shanghai.com
Official LinkedIn Account:CPIC China
Registration Inquiry
Zhao Yaxian: 19910727558
Ding Jieyi: 19910274182
Weng Qi: 17751479618
Business Cooperation
Li Jiayuan: 17718589627
Li Zhen: 13522802756
Zhang Mingyue: 15101686528
Ning Yuanyuan: 18710112302
Liu Yang: 18010079080
Yang Yunting: 17365430165
Media Cooperation
Li Chun: 19910611152